Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Alveolar macrophages (AMs), localized at the pulmonary air-tissue interface, are one of the first lines of defense that interact with inhaled airborne pathogens such as influenza viruses. By using a new CD169-DTR transgenic mouse strain we demonstrate that specific and highly controlled in vivo ablation of this myeloid cell subset leads to severe impairment of the innate, but not adaptive, immune responses and critically affects the progression of the disease. In fact, AM-ablated mice, infected with a normally sublethal dose of PR8 influenza virus, showed dramatically increased virus load in the lungs, severe airway inflammation, pulmonary edema and vascular leakage, which caused the death of the infected animals. Our data highlight the possibilities for new therapeutic strategies focusing on modulation of AMs, which may efficiently boost innate responses to influenza infections.

Original publication




Journal article


Eur j immunol

Publication Date





2003 - 2012


Alveolar macrophages, CD169-DTR, In vivo depletion, Influenza, Transgenic mouse, Adaptive Immunity, Animals, CD8-Positive T-Lymphocytes, Dendritic Cells, Female, Influenza A Virus, H1N1 Subtype, Lung, Macrophages, Alveolar, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections, Sialic Acid Binding Ig-like Lectin 1, Viral Load